BIOCHEMICAL SOCIETY TRANSACTIONS that (2 h) of similar cholesterol-rich liposomes (Senior & Gregoriadis, 19826). When liposomes were injected intraperitoneally into normal animals, no latent carboxyfluorescein could be recovered in the circulation ; however, when injected similarly into lipoprotein-deficient animals, latent dye was detected in the blood, with a peak of 10% of dose detected after 2 h. Maintenance of liposomal stability in lipoprotein-deficient animals is also supported by studies in oitro, which indicate that [3H]phosphatidylcholinelabelled liposomes incubated with lipoprotein-deficient plasma at 37°C retain both entrapped carboxyfluorescein and [3H]phosphatidylcholine to a greater extent than do those incubated in normal plasma. This was shown by gel chromatography on Ultrogel AcA 34, which separates liposomally bound and HD-lipoprotein-associated [3H]phosphatidylcholine marker, and also entrapped and free carboxyfluorescein (Senior et al., 1983).
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To determine whether other lipoproteins in addition to HD lipoprotein are active in destabilizing liposomes, lipoprotein-deficient plasma (0.5 ml) from 4-aminopyrazolopyrimidine-treated mice was supplemented with mouse HD (188-750pg), low-and intermediate-density (14-34pg) and very-low-density (18-5Opg of protein) lipoproteins in concentrations covering the physiological range and incubated at 37°C with 50p1 of liposomes containing quenched carboxyfluorescein. Duplicate lop1 samples from the incubation mixtures were diluted phosphate-buffered saline at time intervals, and latent carboxyfluorescein was measured. Only HD lipoproteins were found to destabilize liposomes, as other lipoproteins did not augment loss of latency above that seen by the action of lipoproteindeficient plasma alone. Furthermore, when lipoproteindeficient plasma was heated at 56°C for 30min, and then, before to incubation with liposomes, supplemented with HD lipoproteins, its liposome-destabilizing activity was not restored to its initial value. This confirmed that there is a heat-labile factor in the plasma acting with HD lipoprotein to bring about maximum vesicle destabilization (Senior et al., 1983; Damen et al., 1981) .
An example of plasma lipoprotein deficiency occurring in man is phosphatidylcholine :cholesterol acyltransferase deficiency characterized by low concentrations of plasma HD lipoproteins. A sample of plasma from a patient with phosphatidylcholine :cholesterol acyltransferase deficiency on incubation with phosphatidylcholine liposomes was less active in promoting solute release than was plasma from a normal control. Our results suggest that clinical application of drug-containing liposomes must take into account fluctuations in plasma HD lipoproteins, and perhaps other factors which could alter liposomal membrane permeability in vivo and thus influence drug fate and effect.
Liposomes have often been proposed for use as drug carriers (Mayhew & Papahadjopoulos, 1983) . The ability of liposomes to encapsulate drugs within their internal aqueous space or in the lipid bilayer makes them a versatile carrier system which may improve the efficacy of drugs in one of two ways. First, by acting as a slow release system, liposomes may modify the pharmacokinetics of drugs so as to prolong effective plasma drug levels. Second, being a microscopic carrier system, liposomes may transport and deliver drugs directly to cells.
The successful use of the second approach requires first that liposomes be directed specifically to the target cell, and second that they be capable of delivering the encapsulated drug to the cells once they reach them. Both of these characteristics can be examined by experiments in uitro, and we will here review our investigations which have been carried out to achieve these aims.
The targeting of liposomes to specific cell types is most readily achieved by attaching ligands to the liposome surface which will bind to determinants on the plasma membrane of the target cell. The most versatile ligands available are antibodies which can be produced to a wide * Present address : Department of Haematology, St. Bartholomews Hospital, West Smithfield, London ECI, U.K. variety of determinants on cells. In particular, monoclonal antibodies can be highly specific and preparations of monoclonals, unlike polyclonal antisera, contain very little antibody with no reactivity for the target antigen. We have developed several methods for the attachment of antibodies to liposomes. Our first procedure (Heath et a[., 1981) involved the use of periodate-oxidized glycosphingolipids in the liposome membrane, which can be conjugated to antibodies by reductive amination with sodium cyanoborohydride. Subsequently, more efficient procedures were developed which involved thiol conjugation methods. In the first (Martin et al., 1981) , phosphatidylethanolamine was modified by reaction with succinimidyl 3-(2-pyridyldithi0)propionate. The resultant modified lipid was incorporated into liposomes and reacted efficiently with rabbit Fab' to form a dithiol bridge which can be reduced by glutathione or other thiol-reducing agents. A more stable linkage was achieved by a similar procedure in which phosphatidylethanolamine was reacted with succinimidyl 4-(p-maleimidopheny1)butyrate to give a modified phospholipid with an alkylating moiety. This lipid, after incorporation into liposomes, reacted rapidly with rabbit Fab' to form a thioether bond which cannot be reversed by reducing agents. We have also efficiently conjugated monoclonal antibodies to liposomes bearing the same maleimide derivative . Conjugation requires the introduction of thiol residues on to the antibody by reaction with succinimidyl 3-(2-pyridyldithio)propionate and mild reduction with dithiothreitol at pH4.5 (Carlsson et al., 1978) . The latter method is now most frequently used in this laboratory as it is both efficient and can be applied to any protein which can be thiolated including antibodies and bovine serum albumin (Shek & Heath, 1983) .
Our first experiments on cell binding were done with large unilamellar liposomes prepared by reverse-phase evaporation (Szoka & Papahadjopoulos, 1978) and directed to human erythrocytes (Heath et al., 1980) . We showed that the antibody can increase erythrocyte binding of liposomes by up to 300-fold. We have also demonstrated with erythrocytes as a model target cell, that the functional affinity of liposomes for the cell surface is greater than the intrinsic affinity of the monovalent antigen-binding site . This shows that liposomes may bind more avidly to the cell surface than the antibody from which they are derived. More recently, we have studied a number of cultured cell lines to determine whether monoclonal antibodies to different determinants can enhance liposome association with the cells. Conjugation to an anti-H2Kk monoclonal antibody increases by 20-fold the association of targeted large unilamellar liposomes with L929 fibroblasts (Heath etal., 1983) , R1.l T-lymphoma cells or CBA mouse splenocytes (Papahadjopoulos er al., 1982) . A non-specific antibody had no effect on association, and the anti-H2Kk antibody had no effect on liposome association with cells lacking the target antigen. Liposomes conjugated to monoclonal antibody showed increased association with K562 cells regardless of antibody specificity (Bragman et al., 1983) . This cell line seems to express an F, receptor which can interact with antibody conjugated to liposomes. Large liposomes conjugated to anti-glycophorin also interacted with K562, presumably via a dual interaction with the glycophorin A molecule and the F, receptor in the cell membrane. Inhibition studies showed that the association of liposomes with the cells via the F, receptor could readily be blocked with human immunoglobulin G. However, the association of liposomes via the F, receptor and glycophorin A required both ligands for effective competition.
Liposomes conjugated to anti-thy 1.1 associate with AKR/J SL2 lymphoma cells in 10-fold greater amounts than vesicles conjugated to a non-specific antibody (Matthay et al., 1982 (Matthay et al., , 1984 . The increase in association by the antibody occurs equally for liposomes 0.44pm or 0.05 pm in diameter. The association of the targeted liposomes with the cells can be blocked with soluble anti-thy 1.1 antibody.
The specific association of targeted liposomes with cultured cells prompted us to examine whether these liposomes can deliver their contents to the cells. Such determination requires a method which can demonstrate functional delivery of the liposome contents. Since we were interested in the targeting of cytotoxic drugs we chose to use a growth-inhibition assay for the delivery of a cytotoxic drug. The delivery of such agents by liposomes has not formerly proved very successful (Allen et al., 1981) . The only class of drugs which has been used with some success in liposomes is the pteridine antifolates. Leserman er al. (1981) have demonstrated that methotrexate is delivered by targeted liposomes more effectively to target cells than to non-specific cells. The disadvantage of using methotrexate is its potency in the free form, which makes the drug more effective than encapsulated drug in most cases. We therefore chose to use methotrexate-y-aspartate, a derivative of methotrexate which is an effective inhibitor of dihydrofolate reductase, but is unable to enter cells (Piper et al.,  1982) . With large liposomes. targeted with anti-H2K antibody, we were able to make this drug 10-fold more effective for growth inhibition of L929 fibroblasts than it is in the free form. Moreover, the drug in targeted liposomes was 20-fold more effective than the drug in liposomes conjugated to a non-specific antibody. Drug efficacy was dependent on the encapsulation of the compound, since a mixture of free drug and empty anti-H2Kk-conjugated liposomes was no more effective than the free compound. Growth inhibition was due to an antifolate since the effects could be abolished by rescue of the cells with folinic acid.
The mechanism of drug delivery appeared to involve lysosomal processing of the liposomes, because ammonium chloride. inhibited the effect of the encapsulated drug. As yet, neither the mechanism of drug transfer, nor the mechanism of ammonium chloride inhibition are clear, though several possible mechanisms have been proposed (Heath et al., 1983a) .
We have also examined drug delivery to AKR/J SL2 cells with liposomes conjugated to anti-thy 1.1 (Matthay et al.,  1982) . Interestingly, we find that only targeted small liposomes deliver drugs effectively, while targeted large liposomes are ineffective for drug delivery. We have also observed a similar effect for drug delivery to R1.1 cells with liposomes conjugated to anti-H2Kk (Matthay et al., 1984) . Machy & Leserman (1983) have also demonstrated that small liposomes deliver methotrexate more effectively than large liposomes.
Large liposomes conjugated to anti-glycophorin or to nonspecific antibody also deliver methotrexate-y-aspartate effectively to K562 cells (Bragman et a[., 1984) . Moreover, the inhibition of drug delivery by soluble ligands and the inhibition of liposome cell association, described above, followed a very similar pattern.
In conclusion, our recent work has demonstrated that appropriately formulated liposomes can be cell-specific cytotoxic agents. Ligands can direct the liposomes to specific cell surface determinants and thereby enhance liposome-cell association. Encapsulated pteridine antifolates are effectively delivered to the cells by a process which appears to involve endocytosis and lysosomal processing of the liposomes. The choice of a pteridine-antifolate which is transport negative (methotrexate-y-aspartate) can result in liposome preparations whose drug content is more effective than it would be in the free form. This will be beneficial for future use of targeted liposomes in situations where the effects of drug which leaks from the liposomes must be minimized.
In the future, we hope to examine the usefulness of targeted liposomes as cell-specific cytotoxic agents in vivo. Clearly there are many additional problems which include the stability of the liposomes, the avoidance of hepatic uptake of liposomes, and the ability of liposomes to pass diffusional barriers in order to reach the target tissue or organ.
Liposome stability has been maximized and hepatic clearance of liposomes has been minimized by the use of small liposomes prepared from compositions which resist lipoprotein-mediated breakdown (Gregoriadis & Senior, 1980; Hwang et al., 1982) . However, for ligand targeted liposomes, additional development may be required to ensure that the targeting ligands do not themselves promote uptake by the liver or other non-target organs. The accessibility of target cells to liposomes may prove a difficult problem, since the permeability of non-fenestrated vascular endothelium is highly restricted. Initially, attempts to direct liposomes may be best restricted to targets which are not sequestered behind endothelial barriers, for example the lymphoid system. Alternatively, appropriate choice of the route of administration, such as subcutaneous injection, may circumvent the barriers. Subsequently, more detailed knowledge of factors which control vascular permeability (Simionescu el al., 1978; Heltranu et al., 1982) may allow selective promotion of liposome extravasation.
In summary, whilst many problems have yet to be solved before targeted liposomes can be used clinically, we are optimistic that the study of liposomes will contribute significantly to the development of drug delivery systems.
VOl. 12
One of the often-cited advantages of liposomes as drug carriers is the low, or absent, immunogenicity of the liposomes themselves. Indeed we have found, as have others, that repeated injection of liposomes does not normally produce anti-liposome antibodies in rabbits (reviewed by Alving, 1983~). However, we have observed that a single injection of liposomes containing lipid A from endotoxin results in anti-liposome antibodies in nearly every animal tested (Schuster et al., 1979) . By injecting liposomes containing lipid A, monoclonal anti-liposome antibodies were obtained that had specificities similar to those of polyclonal antibodies in antiserum (Banerji et al., 1982; Friedman et al., 1982) .
Upon testing the specificities of numerous polyclonal and monoclonal antibodies after immunizing with different liposomes, it was found invariably that the antibodies reacted best with the particular liposome composition used for immunization (Banerji et al., 1982) . Despite this, all polyclonal and monoclonal anti-liposome antibodies examined to date were quite similar in that they had a phosphatebinding site, and were inhibited by a spectrum of soluble phosphorylated compounds, including phosphocholine (but not choline), inositol hexaphosphate (but not inositol), nucleotides (ATP>AMP), and even to a slight extent by sodium phosphate and sodium sulphate (Banerji et af.,  1982) .
Recently I reported the occurrence of naturally occurring 'anti-liposome' antibodies in a human serum (Alving, 19836) . I proposed that antibodies against phospholipids (and other lipids, including glycolipids and cholesterol) represent a unique set of previously unrecognized antibodies that may have important biological functions. As an example of one possible biological function, a new theory of aging was proposed in which the keystone was the gradual appearance of natural antibodies against lipids (Alving, 19836) .
In the present paper I present further data on the prevalence and specificity of naturally occurring antibodies against PC* and PS in normal human sera.
The sources of lipids and methods for preparation of liposomes have been described in detail elsewhere (Alving et al., 1984) . The liposomes were multilamellar hand-shaken vesicles in which phospholipid, CHOL, and either DCP or SA were present in molar proportions of 1 : 0.75 : 0.1 1. The phospholipid was lOmM with respect to the aqueous volume (0. I5M-NaCI or 0.308~-glucose) used to suspend the liposomes. The phospholipid was egg (or dipalmitoyl) PC, bovine brain SM or bovine brain PS.
The method for measuring complement-dependent immune damage to liposomes has also been described (Alving et al., 1984) . The assay method was modified only in that the initial pH of the glucose assay reagent was adjusted to 7.0 instead of 7.4. The liposomes containing PS or egg PC were less leaky at the lower pH.
Adsorption of serum antibodies by liposomes was performed by incubating 1.5ml of fresh serum (unheated) with 0.15ml of liposomes swollen in 0.15hl-NaCl. Before incubation with serum, the liposomes were centrifuged into a pellet (27000g for IOmin) and the supernatant was discarded. The serum added to the pellet contained added MgCl,, 6H,O (final concn. 2 m~) and CaC1, (final concn. 0 . 3 m~) . After incubation at room temperature (22°C) for 90min, the liposome and serum suspension was centrifuged at 27000g. The subnatant (adsorbed serum) under the floating liposomes was removed, and the serum was adsorbed with liposomes again. After the second adsorption the serum was clarified by centrifugation again to ensure removal of all liposomes and was stored at -70°C before use.
The complement in the serum was intact before the adsorption process. After adsorption with liposomes, the haemolytic complement titre decreased when anti-liposome antibodies were present, but more than 60% of the
